Gaois

This is a static copy of data that is exported from IATE on an occasional basis. It should not be assumed that information provided about an entry here will always correspond to the current version of the entry in IATE. That current version can be checked by clicking on the link on the upper right hand side of each entry. More information »

1 result

  1. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #599236

    IATE #3599599
    spícephróitéin réamhleá SARS-CoV-2 chobhsaithe Reference Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    SARS-CoV2 prefusion Spike delta TM | stabilised SARS-CoV-2 pre-fusion S protein
    en
    Definition pre-fusion spike protein of SARS-CoV-2 as it has been stabilised in order to be used in a vaccine Reference COM-Terminology Coordination, based on:- Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, et al. 'Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study' (18.6.2021). Lancet Infect Dis. April 19, 2021- 'Supplementary appendix 2' (18.6.2021). Supplement to: Goepfert PA, Fu B, Chabanon A-L, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infect Dis 2021; published online April 19. https://doi.org/10.1016/S1473-3099(21)00147-X
    CoV2 preS dTM
    mul